At a glance
ClinicalIndex Comparison RecordPhase 4Recruiting· 25 target
Drug / intervention
Daratumumab and corticosteroid treatmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Single-arm Exploratory Study of CD38 (Daratumumab) Monoclonal Antibody (Daratumumab) Combined Corticosteroid in the Treatment of Acquired Hemophilia A (AHA)
Institute of Hematology & Blood Diseases Hospital, China·interventional·Posted May 9, 2023·Updated Aug 5, 2025
In Brief
A Phase 4 clinical trial evaluating Daratumumab and corticosteroid treatment for Acquired Hemophilia. Currently recruiting, targeting 25 participants across 1 site.
Detailed Summary
To evaluate the time of response, sustained remission rate and relapse rate of CD38 monoclonal antibody (Daratumumab) combined corticosteroid in the treatment of AHA. To evaluate the safety of CD38 monoclonal antibody in the treatment of AHA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcquired Hemophilia
CountriesChina
Collaborators--
Timeline
Phase 4Recruiting
2024202520262027
First PostedMay 2023
Enrollment StartMay 2023
TodayJul 2026
Primary CompletionApr 2027
Study CompletionOct 2027
First PostedMay 9, 2023
Enrollment StartMay 22, 2023
Primary CompletionApr 30, 2027
Study CompletionOct 31, 2027
TodayJul 1, 2026
Enrollment to primary: 3.9 yearsPosted 3.1 years agoPrimary completion in 10 months
Interventions
Daratumumab and corticosteroid treatmentdrug
Daratumumab and corticosteroid treatment